Prioritization of cancer antigens: Keeping the target in sight

Expert Review of Vaccines

Volumn 8, Issue 12, 2009, Pages 1657-1661

  Lang, Joshua M ^b   Andrei, Adin Cristian ^b   McNeel, Douglas G ^a  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Immunotherapy; Tumor vaccine; Tumor associated antigen

Indexed keywords

T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; TUMOR REJECTION ANTIGEN;

ACTIVE IMMUNIZATION; BIOLOGICAL ACTIVITY; CARCINOGENESIS; DRUG TARGETING; FUSION GENE; HUMAN; IMMUNOMODULATION; MASTOCYTOMA; NATIONAL HEALTH ORGANIZATION; NONHUMAN; NOTE; ONCOGENE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNOLOGY;

EID: 73849150225     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.134     Document Type: Note

References (19)

1. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009).
2. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365 (1994).
3. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173(6), 1373-1384 (1991).
4. Ruf J, Czarnocka B, De Micco C, Dutoit C, Ferrand M, Carayon P. Thyroid peroxidase is the organ-specific 'microsomal' autoantigen involved in thyroid autoimmunity. Acta Endocrinologica 281, 49-56 (1987).
5. Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. Curr. Opin. Immunol. 8, 637-642 (1996).
6. Sahin U, Tureci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA 92(25), 11810-11813 (1995).
7. Jongeneel V. Towards a cancer immunome database. Cancer Immun. 1, 3 (2001).
8. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated antitumor immune responses. Eur. J. Immunol. 37(3), 675-685 (2007).
9. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
11. Kish L. Survey Sampling. Wiley Interscience, NY, USA (1995).
12. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748), 644-648 (2005).
13. Simons JW, Carducci MA, Mikhak B et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormonenaive prostate cancer. Clin. Cancer Res. 12(11 Pt 1), 3394-3401 (2006).
14. Fong L, Kwek SS, O'Brien S et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 69(2), 609-615 (2009).
15. Yuan J, Gnjatic S, Li H et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105(51), 20410-20415 (2008).
16. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15, 3363-3367 (1997).
17. Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353(12), 1224-1235 (2005).
18. Small EJ, Schellhammer PF, Higano CS, Neumanaitis J, Valone F, Hershberg R. Results of a placebo-controlled Phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 23(16S), 4500 (2005).
19. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Invest. Drugs 18(7), 1001-1011 (2009).